GlobeNewswire

Nordea Bank AB: First Quarter Results 2018

Dela

COPENHAGEN, Denmark, April 25, 2018 (GLOBE NEWSWIRE) -- 

Paris Stock Exchange : XHFT

First Quarter Results 2018

CEO Casper von Koskull's comments on the results:

"2016 and 2017 were characterised by significant investments to improve our compliance and risk operations as well as a de-risking of the bank. These activities have had a meaningful impact on both revenues and costs. Furthermore, this has led to a situation where we have been more internally focused and we now need to get back to focusing more on our customer business. I am satisfied to say that we are now through the most important parts of the de-risking, the risk reduction in Russia, Shipping, Oil and Offshore progressing well, and our International Private Banking arm being divested.

In the first quarter of 2018 we delivered on our cost reductions, our credit quality is the strongest since 2007 and our capital ratios have never been higher. We are confident that net profit will grow in 2018 compared to 2017, as previously stated. As the underlying revenues in the first quarter were softer than expected it is more challenging to reach our full-year revenue guidance. We will therefore have an increased focus on improving the business momentum, while at the same time maintaining our risk and compliance discipline. We reiterate our cost target for 2018 of EUR 4.9bn."

First quarter 2018 vs. First quarter 2017 (First quarter 2018 vs. Fourth quarter 2017)

  • Net interest income EUR 1,053m, -12%; -9% in local currencies (-5%, -5% in local currencies)
  • Total operating income EUR 2,315m, -6%; -4% in local currencies (4%, 4% in local currencies)
  • Total expenses EUR 1,205m, -3%; -1% in local currencies (-11%, -11% in local currencies)
  • Profit before loan losses EUR 1,110m, -9%; -7% in local currencies (28%, 28% in local currencies)
  • Net loan losses EUR 40m, -65%; -63% in local currencies (-44%, -43% in local currencies)
  • Operating profit EUR 1,070m, -3%; -1% in local currencies (34%, 35% in local currencies)
  • Common Equity Tier 1 capital ratio 19.8%, up from 18.8% (up from 19.5%) 
  • Cost/income ratio 52% up from 51% (down 9% points from 61%)
  • Loan loss ratio of 7 bps, down from 14 bps (down 2 bps from 9 bps)
  • Return on equity 10.0%, down from 10.3% (up 2.3% points from 7.7%)
  • Diluted EPS EUR 0.20 vs. EUR 0.21 (EUR 0.20 vs. EUR 0.15)

Exchange rates used for Q1 2018 for income statement items are for DKK 7.4468, NOK 9.6366 and SEK 9.9765.

Nordea Q1 2018 (PDF):

http://www.rns-pdf.londonstockexchange.com/rns/0424M_-2018-4-25.pdf

For further information:
Casper von Koskull, President and Group CEO, +46 10 157 1020      
Christopher Rees, Group CFO, +45 5547 2377 

Rodney Alfvén, Head of Investor Relations, +46 72 235 05 15 
Sara Helweg-Larsen, Head of Group Communications,   +45 2214 0000

The information in this press release is such, which Nordea Bank AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07.00 CET on 25 April 2018.

This information is provided by RNS
The company news service from the London Stock Exchange




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nordea Bank AB (publ) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum